查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
2023-2030 年全球类毒素疫苗市场
市场调查报告书
商品编码
1272775

2023-2030 年全球类毒素疫苗市场

Global Toxoid Vaccine Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 195 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概览

全球类毒素疫苗市场预计到 2022 年将达到 55.856 亿美元，到 2030 年将达到 82.672 亿美元。 预计该市场在预测期内（2023-2030 年）的复合年增长率为 5.1%。 主要市场参与者的存在，占亚太地区类毒素疫苗市场份额的大部分，确保该地区以高复合年增长率增长。

例如，2022 年 10 月，印度领先的生物技术公司之一 Panacea Biotec 与联合国儿童基金会签署了一项协议，供应经世卫组织预审的完整液体五价疫苗 Easyfive-TT (DTwP-HepB-Hib)。美国卫生组织 (PAHO) 长期供应奖，价值 1.273 亿美元（约合 1,040 卡路里的印度卢比）。

此外，2022 年 9 月，在 Covid 疫苗取得成功后，印度血清研究所将专注于白喉、百日咳和破伤风 (Tdap) 疫苗设计。 该公司已将 2-3 期临床试验数据提交给印度药物管制委员会 (DCGI) 的专家小组，以批准生产该疫苗。 因此，数据表明，在整个预测期内，亚太地区的类毒素市场将以高复合年增长率增长。

全球类毒素疫苗市场是针对使用类毒素作为抗原以针对某些细菌性疾病（如破伤风）产生免疫反应的疫苗。 这种疫苗对于保护成人和 7 岁以上的儿童免受破伤风特别有效。

由于传染病的流行、对疫苗接种益处的认识提高以及政府主导的旨在促进疫苗接种计划的努力等多种因素，预计类毒素疫苗市场将大幅增长。. 此外，市场主要参与者正在进行的研发活动和新产品的推出预计将进一步推动全球类毒素疫苗市场的增长。

市场动态

政府资助的传染病预防计划的增加预计将推动全球类毒素疫苗市场的增长

针对类毒素疫苗的政府举措，例如孕产妇、新生儿和新生儿破伤风根除 (MNTE) 计划，在推动全球类毒素疫苗市场的增长方面发挥着关键作用。 孕产妇和新生儿破伤风 (MNT) 是一种危及生命的疾病，可由不洁分娩和脐带护理做法引起。 MNTE 倡议旨在将 MNT 病例数量减少到如此低的水平，以至于该疾病不再是主要的公共卫生问题。

各国政府和世界卫生组织 (WHO) 等国际组织通过资助免疫计划和公共卫生运动积极支持 MNTE 倡议。 由于这些努力，全球类毒素疫苗市场预计在预测期内将显着增长。

全球类毒素疫苗市场增长可能因对这些疫苗的不同诱导过敏反应而面临限制

破伤风类毒素疫苗的使用受到注射部位疼痛和发红等局部反应以及发烧、疲劳和肌痛等全身反应的限制。 对疫苗的严重过敏反应很少见，但一小部分人可能会担心。

此外，由于疫苗接种的普及，破伤风的发病率显着下降，疫苗需求也随之减少。 破伤风类毒素疫苗市场的特点是在占有很大份额的合同市场和私人市场之间存在分歧。

COVID-19 影响分析

类毒素疫苗市场受到大流行的影响好坏参半。 对破伤风类毒素疫苗的需求一直稳定，因为它已被纳入常规免疫接种，而对白喉类毒素疫苗的需求随着世界许多地区白喉发病率的下降而下降。

儘管存在这种情况，但由于持续需要疫苗接种计划来控制传染病，全球类毒素疫苗市场预计将继续稳步增长。. 预计大流行对市场的总体影响是温和的。

俄乌衝突分析

全球类毒素疫苗市场并未受到俄罗斯和乌克兰之间持续衝突的显着影响。 因为大部分生产和分销都位于衝突地区之外。 然而，据报导，该地区的衝突扰乱了供应链，并导致难以获得包括疫苗在内的医疗用品。

此外，在一些地区，医院和诊所等医疗保健设施因衝突而遭到破坏或摧毁。 这使得难以为民众提供必要的医疗保健服务，包括疫苗接种计划。

内容

第 1 章研究方法和范围

  • 调查方法
  • 调查目的和范围

第 2 章定义和概述

第 3 章执行摘要

  • 按疾病分类
  • 按组成
  • 最终用户
  • 按地区

第四章市场动态

  • 影响因素
    • 主持人
      • 政府资助的传染病预防计划的增加预计将推动全球类毒素疫苗市场的增长
    • 约束因素
      • 类毒素疫苗引起的过敏反应可能会限制全球类毒素疫苗市场的增长
    • 机会
    • 影响分析

第五章行业分析

  • 波特的五力分析
  • 供应链分析
  • 价格分析
  • 法律法规分析

第 6 章 COVID-19 分析

  • COVID-19 分析
    • COVID-19 之前的情景
    • 当前的 COVID-19 情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格和动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第7章疾病

  • 破伤风
  • 白喉
  • 百日咳

第八章行动

  • 白喉、破伤风、百日咳 (DtaP)
  • 白喉和破伤风 (DT)
  • 破伤风、白喉、百日咳 (Tdap)
  • 单价破伤风类毒素 (TT)
  • 破伤风和白喉 (Td)

第 9 章最终用户

  • 医院和诊所
  • 政府机构
  • 其他

第10章按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第11章竞争格局

  • 竞争场景
  • 市场定位/份额分析
  • 併购分析

第12章公司简介

  • 赛诺菲公司
    • 公司概况
    • 产品组合和说明
    • 财务摘要
    • 主要发展状况
  • Serum Institute of India Pvt. Ltd.
  • Panacea Biotec
  • Biological E Limited
  • GlaxoSmithKline
  • Merck & Co. Inc.
  • Astellas Pharma Inc.
  • Bharat Biotech
  • Dano Vaccines
  • Abbot

第13章 附录

简介目录
Product Code: PH2169

Market Overview

The global toxoid vaccine market reached US$ 5,585.6 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 8,267.2 million by 2030. The market is expected to exhibit a CAGR of 5.1% during the forecast period (2023-2030). The presence of key market players holding the majority of the toxoid vaccine market share in the Asia-Pacific region ensures the growth of this region at a high CAGR rate.

For instance, in October 2022, Panacea Biotec, one of India's leading biotechnology companies, received long-term supply awards worth US$ 127.30 million (around INR 1,040 Crore) from UNICEF and Pan American Health Organization (PAHO) for the supply of its WHO pre-qualified fully liquid Pentavalent vaccine, Easyfive-TT (DTwP-HepB-Hib).

Moreover, in September 2022, after a successful run with its covid vaccine, the Serum Institute of India focused on designing a vaccine for Diphtheria, Pertussis, and Tetanus (Tdap). The company has presented its phase 2-3 clinical trial data to the Drugs Control General of India (DCGI)'s expert panel seeking permission to manufacture the vaccines. Thus, the data indicate that the Asia-Pacific toxoid market will grow at a high CAGR throughout the forecast period.

The global toxoid vaccine market is the market for vaccines that use toxoids as antigens to create an immune response against specific bacterial diseases, such as tetanus. This type of vaccine is particularly effective at providing protection against tetanus in adults and children aged seven years or older.

The market for toxoid vaccines is expected to grow at a significant rate due to several factors, including the rising prevalence of infectious diseases, increased awareness of the benefits of vaccination, and government-led initiatives aimed at promoting vaccination programs. In addition, ongoing research and development activities and new product launches by major players in the market are expected to further boost the growth of the global toxoid vaccine market.

Market Dynamics

The rising number of government-funded programs to prevent infectious diseases is expected to drive the growth of the global toxoid vaccine market

Government initiatives for toxoid vaccine, such as the Maternal and Neonatal Tetanus Elimination (MNTE) initiative, play a crucial role in driving the global toxoid vaccine market growth. Maternal and Neonatal Tetanus (MNT) is a life-threatening disease that can occur due to unclean deliveries and umbilical cord care practices. The MNTE initiative aims to reduce the number of MNT cases to such low levels that the disease is no longer a major public health problem.

Governments and international organizations, such as the World Health Organization (WHO), have been actively supporting the MNTE initiative by providing funding for immunization programs and public health campaigns. As a result of these initiatives, the global toxoid vaccine market is expected to grow significantly over the forecast period.

The global toxoid vaccine market growth may face constraints due to allergic reactions caused by these vaccines.

The use of the tetanus toxoid vaccine is limited by the occurrence of local reactions such as pain and redness at the site of injection, as well as systemic reactions like fever, fatigue, and muscle pain. Although severe allergic reactions to the vaccine are rare, they can be a concern for a small percentage of people.

Moreover, the incidence of tetanus has declined significantly due to widespread vaccination, resulting in a reduction in demand for the vaccine. The market for tetanus toxoid vaccine is characterized by a dichotomy between the contractual market, which holds a significant share, and the private market.

COVID-19 Impact Analysis

The toxoid vaccine market has experienced a somewhat mixed impact from the pandemic. While the demand for tetanus toxoid vaccines has remained stable due to their inclusion in routine immunization schedules, the demand for diphtheria toxoid vaccines has declined because of reduced diphtheria incidence in many areas worldwide.

Despite this, the global toxoid vaccine market is projected to continue growing at a steady pace because of the ongoing necessity for vaccination programs to manage infectious diseases. The pandemic's overall impact on the market is predicted to be moderately significant.

Russia-Ukraine Conflict Analysis

The global toxoid vaccine market has not been significantly affected by the ongoing conflict between Russia and Ukraine, as most of the production and distribution is situated outside the conflict zone. However, there have been reports of disruptions in supply chains and difficulties in accessing medical supplies, including vaccines, due to the conflict in the region.

Furthermore, the conflict has resulted in damage or destruction of healthcare facilities, such as hospitals and clinics, in some areas. This has made it challenging for the country to provide necessary healthcare services, including vaccination programs, to the population.

Segment Analysis

The global toxoid vaccine market is segmented based on disease, composition, end user, and region.

The diphtheria, tetanus, and pertussis (DtaP) segment is expected to hold the highest market share for the global toxoid vaccine market.

The Diphtheria, Tetanus, and Pertussis (DTaP) segment is expected to be the dominant segment in the global toxoid vaccine market, holding 44.2% of the market share over the forecast period. DTaP is a vaccine that helps children under the age of seven develop immunity against three deadly diseases caused by diphtheria, tetanus, and whooping cough (pertussis). The low cost of the vaccine, increasing tetanus cases, and its availability in low-resource economies such as Africa are driving the growth of the DTaP vaccine segment.

In the United States, there are currently seven licensed pediatric DTaP vaccines being used: Daptacel, Infanrix, Kinrix, Pediarix, Pentacel, Quadracel, and Vaxelis. The growth of the DTaP vaccine segment during the forecast period is attributed to the increasing prevalence of diphtheria, tetanus, and pertussis, product launches, rising demand for combination vaccines, and high adoption of DTaP vaccines.

Geographical Analysis

The presence of major players to dominate the North America region.

The toxoid vaccine market is expected to grow significantly in North America region over the forecast period due to the presence of key market players who hold a major global toxoid market share. The market players have implemented various market strategies such as collaborations, disease launches, and acquisitions to expand their reach and increase their toxoid vaccine market share. It is predicted that North America will dominate the global toxoid vaccine market by acquiring around 2/5th of the market share.

For instance, in June 2022, GSK plc, a global pharmaceutical company, invested a significant amount of over US$1.2 billion in R&D to develop vaccines and medicines to prevent and treat various diseases, including malaria, tuberculosis, HIV, neglected tropical diseases, and diphtheria. All these factors indicate that North America is expected to remain the dominant region in the global toxoid vaccine market.

Competitive Landscape

The major global players in the market include Sanofi S.A., Serum Institute of India Pvt. Ltd., Panacea Biotec, Biological E Limited, GlaxoSmithKline, Merck & Co. Inc., Astellas Pharma Inc., Bharat Biotech, Dano Vaccines, and Abbott.

Why Purchase the Report?

  • To visualize the global toxoid vaccine- market segmentation based on disease, composition, end user and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of global toxoid vaccine market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global toxoid vaccine market report would provide approximately 53 tables, 54 figures and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Disease
  • 3.2. Snippet by Composition
  • 3.3. Snippet by End User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The rising number of government-funded programs to prevent infectious diseases is expected to drive the growth of the global toxoid vaccine market
    • 4.1.2. Restraints
      • 4.1.2.1. The global toxoid vaccine market growth may face constraints due to allergic reaction caused by these vaccines
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Before COVID-19 Scenario
    • 6.1.2. Present COVID-19 Scenario
    • 6.1.3. Post COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Disease

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease
    • 7.1.2. Market Attractiveness Index, By Disease
  • 7.2. Tetanus
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Diphtheria
  • 7.4. Pertussis

8. By Composition

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Composition
    • 8.1.2. Market Attractiveness Index, By Composition
  • 8.2. Diphtheria, Tetanus, and Pertussis (DtaP)
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Diphtheria and Tetanus (DT)
  • 8.4. Tetanus, Diphtheria, and Pertussis (Tdap)
  • 8.5. Monovalent Tetanus Toxoid (TT)
  • 8.6. Tetanus and Diphtheria (Td)

9. By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.1.2. Market Attractiveness Index, By End User
  • 9.2. Hospitals And Clinics
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Government Organizations
  • 9.4. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Composition
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. The U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Composition
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. The U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Composition
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Composition
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Composition
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Sanofi S.A.*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Serum Institute of India Pvt. Ltd.
  • 12.3. Panacea Biotec
  • 12.4. Biological E Limited
  • 12.5. GlaxoSmithKline
  • 12.6. Merck & Co. Inc.
  • 12.7. Astellas Pharma Inc.
  • 12.8. Bharat Biotech
  • 12.9. Dano Vaccines
  • 12.10. Abbot

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us